Q1 EPS Estimate for Beam Therapeutics Increased by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Investment analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for Beam Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($1.20) per share for the quarter, up from their previous forecast of ($1.26). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($1.23) EPS, Q3 2025 earnings at ($1.22) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.89) EPS and FY2026 earnings at ($5.08) EPS.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.16. The business had revenue of $30.00 million for the quarter, compared to the consensus estimate of $16.47 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The company’s quarterly revenue was down 90.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.73 earnings per share.

Several other equities research analysts have also issued reports on BEAM. Jones Trading raised shares of Beam Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research report on Monday, March 10th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Monday, March 10th. Sanford C. Bernstein raised shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Guggenheim reaffirmed a “buy” rating and set a $78.00 price target on shares of Beam Therapeutics in a report on Thursday, February 27th. Finally, Royal Bank of Canada raised their price target on shares of Beam Therapeutics from $24.00 to $26.00 and gave the company a “sector perform” rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Beam Therapeutics presently has a consensus rating of “Buy” and an average target price of $50.82.

Beam Therapeutics Stock Up 4.6 %

Beam Therapeutics stock opened at $23.64 on Thursday. Beam Therapeutics has a 52-week low of $20.84 and a 52-week high of $36.75. The firm has a fifty day moving average of $26.90 and a 200-day moving average of $25.95. The firm has a market capitalization of $2.36 billion, a P/E ratio of -13.43 and a beta of 1.91.

Insider Transactions at Beam Therapeutics

In related news, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the sale, the insider now directly owns 102,968 shares in the company, valued at $2,541,250.24. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John M. Evans sold 30,000 shares of Beam Therapeutics stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the sale, the chief executive officer now owns 908,659 shares in the company, valued at approximately $24,306,628.25. This represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Beam Therapeutics

Several large investors have recently bought and sold shares of BEAM. Atria Investments Inc acquired a new position in Beam Therapeutics during the 3rd quarter valued at about $200,000. Quest Partners LLC increased its stake in Beam Therapeutics by 410.8% during the 3rd quarter. Quest Partners LLC now owns 36,193 shares of the company’s stock valued at $887,000 after buying an additional 29,108 shares during the period. Intech Investment Management LLC acquired a new position in Beam Therapeutics during the 3rd quarter valued at about $512,000. Charles Schwab Investment Management Inc. increased its stake in Beam Therapeutics by 6.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 629,492 shares of the company’s stock valued at $15,423,000 after buying an additional 36,226 shares during the period. Finally, Algert Global LLC increased its stake in Beam Therapeutics by 282.0% during the 3rd quarter. Algert Global LLC now owns 43,523 shares of the company’s stock valued at $1,066,000 after buying an additional 32,130 shares during the period. Institutional investors and hedge funds own 99.68% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.